AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00137696 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with inactivated polio vaccine
Study NCT00137696 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with inactivated polio vaccine
Study NCT00137696 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Collection of serum
Study NCT00137696 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of serum
Study NCT00581828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
Study NCT02822300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Coppertone (BAY987517)
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation: SR15-74_R84-086)
Study NCT03186014 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fully covered irradiation stent
Description: A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
Study NCT00070252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given PO
Study NCT00070252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV
Study NCT00070252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00070252 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT00070252 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given orally (PO)
Study NCT05532267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Description: an immediate release film-coated tablet containing 750 mg Ciprofloxacin
Study NCT05532267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciproxin 750 mg
Description: an immediate release film-coated tablet containing 750 mg Ciprofloxacin
Study NCT00640640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pascal Dynamic Contour Tonometer
Description: Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
Study NCT00640640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab
Description: measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
Study NCT00640640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
Study NCT00997425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Door cover/Floor cover
Description: Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.~Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door.
Study NCT03147313 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MTS Medical UG Orthogold 100
Description: 300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
Study NCT03147313 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Extracorporeal shock wave treatment will be faked.
Study NCT02427724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 2.5%/prilocaine 2.5% topical anesthetic
Study NCT03264209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smart After-Care (Mobile health)
Description: Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
Study NCT02427724 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 7%/tetracaine 7% topical anesthetic
Study NCT02427724 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo vehicle
Study NCT02427724 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q-switched 532nm Laser
Study NCT03946033 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunoscore Colon Test
Description: Immunoscore Colon is a CE-marked in-vitro diagnostic test, allowing the quantification of CD3 and CD8 positive cells in formalin-fixed paraffin-embedded (FFPE) tissue samples of primary colon cancer. The test uses immunohistochemistry, digital pathology techniques and a dedicated software.
Study NCT04720846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Matrix-based physical therapy
Description: Matrix-based physical therapy will be physical therapy that is based on the matrix categorization of the patient (stiff vs. mobile hips, weak vs. strong hips) and involves instructions on the amount of time that should be spent doing stretching and strengthening therapy.
Study NCT04720846 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard-of-care physical therapy
Description: Physical therapy that is being conducted as standard-of-care
Study NCT04720846 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard-of-care physical therapy
Description: Physical therapy that is being conducted as standard-of-care
Study NCT02427724 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Q-switched 532nm Laser
Study NCT02312765 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AirCare App
Description: Tablet software to encourage adherence and support
Study NCT02178046 — intervention group
Intervention type: DEVICE
Intervention: optical measurements
Description: Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
Study NCT02121288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
Study NCT02389205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: kinesio group
Description: kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.~The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc.
Study NCT02121288 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
Study NCT00755157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
Study NCT00755157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
Study NCT02135146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte 3ml/kg/hr group
Description: This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
Study NCT03653572 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Ultrasound exam
Description: Eligible subjects will be positioned for their ultrasound exam, which will take a similar amount of time and be performed in a similar manner as standard of care ultrasound exams at the site. The type and duration of ultrasound exam will be based on the subject's clinical condition.
Study NCT00136825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Study NCT00136825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02135146 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasmalyte 6ml/kg/hr group
Description: This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
Study NCT02063854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NE-58095 IR
Description: NE-58095 IR tablets
Study NCT00571207 — intervention group
Intervention type: DEVICE
Intervention: On-site oral fluid screening devices
Description: Comparison of screening device results to oral and/or blood sample results
Study NCT00571207 — intervention group
Intervention type: BEHAVIORAL
Intervention: Checklist: drug recognition expert
Description: Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
Study NCT04401839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin IV shot
Description: Oxytocin 10 IU I.V shot administered at the time of delivery of the anterior shoulder of the baby
Study NCT04401839 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin IV drip
Description: administration of oxytocin 5 IU units IM (WHO GDG recommendations,2012) and waiting for signs of placental separation
Study NCT04401839 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Amr maneuver
Description: sustained traction downward and posteriorly was applied to anterior and posterior lips of the cervix using ovum forceps for approximately 90 seconds
Study NCT04178993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methamphetamine
Description: In each arm, subjects will receive doses of methamphetamine.
Study NCT04178993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methamphetamine
Description: In each arm, subjects will receive doses of methamphetamine.
Study NCT04178993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: In each arm, subjects will receive methylphenidate capsules.
Study NCT04178993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: In each arm, subjects will receive methylphenidate capsules.
Study NCT02063854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 IR Placebo
Description: NE-58095 IR placebo-matching tablets
Study NCT02063854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR
Description: NE-58095 DR tablets
Study NCT04178993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Description: In each arm, subjects will receive placebo capsules.
Study NCT04178993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: In each arm, subjects will receive placebo capsules.
Study NCT04178993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine
Description: Subjects will receive duloxetine capsules in the duloxetine arm.
Study NCT03983772 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RS blend
Description: The intervention is a proprietary resistant starch blend.
Study NCT02063854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NE-58095 DR Placebo
Description: NE-58095 DR placebo-matching tablets
Study NCT03983772 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is starch.
Study NCT01556061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DMAC
Description: The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
Study NCT02063854 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NE-58095 DR Placebo
Description: NE-58095 DR placebo-matching tablets
Study NCT01482039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sequential ultrasound
Description: Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
Study NCT01482039 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transvaginal ultrasound
Description: Obtain 3 transvaginal ultrasound cervical length measurements
Study NCT01462084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive servo-ventilation (ASV)
Description: Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
Study NCT01462084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bi-Level PAP
Description: Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
Study NCT03118154 — intervention group
Intervention type: OTHER
Intervention: Manual Physical Therapy
Description: Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
Study NCT01556061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DMAC
Description: The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
Study NCT01556061 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CMAC
Description: The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
Study NCT01556061 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CMAC
Description: The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
Study NCT02743546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
Study NCT03601091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Precedex 200 MCG in 2 ML Injection
Description: Infusion therapy of the drug
Study NCT03601091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DORMICUM 5MG/5 ML
Description: Infusion therapy of the drug
Study NCT04151758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic Acid Supplementation
Description: Docosahexaenoic Acid (DHA) will be given at the dose of 500 mg/day (2 ml per day DHA RICH OIL 25% aroma mandorla FoodAR Limbiate, Italy;50% DHA oil obtained from Schyzochitrium sp ; Martek Biosciences Corporation, Columbia, Maryland, USA) to all participants of the study. DHA 2 ml will provide about 16 kcal of energy.
Study NCT04151758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotion of physical activity
Description: All participants will underwent a visit at t0, t1 and t2 in which physical activity will be promoted according to Italian dietary guidelines for childhood obesity.
Study NCT04151758 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Promotion of healthy food habits
Description: All participants will underwent a visit at t0, t1 and t2 in which healthy food habits will be promoted according to Italian dietary guidelines for childhood obesity.
Study NCT03615690 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Mimicking Diet
Description: 5 day reduced calorie diet
Study NCT03615690 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Regular Diet
Description: Regular Diet
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fosaprepitant dimeglumine
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosaprepitant Placebo
Study NCT01594749 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT00810407 — intervention group
Intervention type: DRUG
Intervention: rifabutin
Description: Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.~2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.
Study NCT02611778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ranibizumab
Study NCT02611778 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Study NCT00383149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Intravenous Infusion (IV), 32 mg/m\^2 every 21 days.
Study NCT00383149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Initial dose of 400 mg/m\^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m\^2 IV over 1 hour.
Study NCT01270711 — intervention group
Intervention type: DRUG
Intervention: Study Drug
Description: non interventional study - usage as per usual care
Study NCT01900327 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation
Description: Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
Study NCT01900327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine neoadjuvant
Description: weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
Study NCT01900327 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Upfront pancreato-duodenectomy
Study NCT01900327 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Upfront pancreato-duodenectomy
Study NCT01900327 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine adjuvant
Description: Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
Study NCT04363957 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Brachytherapy Consent Process
Description: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
Study NCT04363957 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Brachytherapy Consent Process
Description: Patients will have the standard clinical brachytherapy consent and education including discussion with their physician.
Study NCT01380548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; once/day; for 12 weeks
Study NCT01380548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Iron alone
Description: Iron (3 mg); once/day; for 12 weeks
Study NCT01380548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-dose 5-aminolevulinic acid with iron
Description: 5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
Study NCT01380548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium-dose 5-aminolevulinic acid with iron
Description: 5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
Study NCT01380548 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High-dose 5-aminolevulinic acid with iron
Description: 5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
Study NCT00229177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ONO-2506
Description: Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
Study NCT00229177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ONO-2506
Description: Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
Study NCT01900327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine adjuvant
Description: Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator